Alirocumab market seen reaching $3.48 billion by 2030

The global alirocumab market is projected to grow from $2.1 billion in 2025 to $3.48 billion by 2030, driven by rising cardiovascular disease, broader use of biologic therapies and expanding reimbursement. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - The alirocumab market is growing as demand rises for targeted lipid-lowering treatments that can help reduce cardiovascular risk. - The market outlook signals continued spending on biologic therapies as health systems respond to higher rates of heart disease and cholesterol-related conditions. - The report points to a bigger commercial opportunity for PCSK9 inhibitors as preventive cardiology expands.

What happened: - The Business Research Company released an alirocumab market report on June 29, 2026, covering market size, trends and global forecasts for 2026-2035. - The report values the market at $2.1 billion in 2025 and projects it will reach $2.32 billion in 2026. - The report forecasts the market will climb to $3.48 billion by 2030. - The report also projects a 10.4% CAGR from 2025 to 2026 and a 10.6% CAGR through 2030.

The details: - Rising LDL cholesterol prevalence, the burden of cardiovascular disease, statin limitations, early biologic adoption in lipid management and updated hypercholesterolemia guidelines supported historical growth. - The aging global population, broader PCSK9 inhibitor pipelines, wider reimbursement for biologics, more home-based self-administration therapies and preventive care programs are expected to support future growth. - Cardiovascular disease includes coronary artery disease, cerebrovascular disease and heart failure. - Sedentary lifestyles are adding to cardiovascular risk by contributing to metabolic issues, excess body fat, hypertension and dyslipidemia. - Alirocumab inhibits proprotein convertase subtilisin/kexin type 9, or PCSK9, and lowers LDL cholesterol. - The American Heart Association projected in June 2024 that cardiovascular disease prevalence among U.S. adults will rise from about 50% currently to 61% by 2050. - Personalized medicine is also supporting demand as clinicians use genetics, biomarkers and lifestyle factors to tailor treatment. - The Personalized Medicine Coalition said in February 2024 that more than one-third of new FDA drug approvals from 2020 to 2023 were personalized therapies. - In 2023, those approvals included 16 treatments for rare diseases and seven oncology drugs. - North America held the largest share of the alirocumab market in 2025 because of advanced healthcare infrastructure and reimbursement policies. - Asia-Pacific is expected to grow fastest over the forecast period because of improving healthcare access, expanding patient populations and rising awareness of cardiovascular disease management. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa. - New 2026 report features include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The company also offered a free sample report and a full report link. - Download a free sample of the alirocumab market report - View the full alirocumab market report

Between the lines: - The forecast suggests demand is being driven by both clinical need and commercial infrastructure, especially reimbursement and self-administration options. - The report frames alirocumab as part of a broader shift toward precision medicine and preventive care, not just cholesterol management. - The strongest growth is likely to come from markets where diagnosis, access and payer support are improving at the same time.

What's next: - The market will likely be shaped by cardiovascular disease prevalence, payer coverage for biologics and the pace of adoption for home-based therapies. - Growth in Asia-Pacific may narrow the gap with North America if access and awareness continue to expand. - The report’s forecast period runs through 2035, signaling more room for pipeline and policy changes to affect the market trajectory.

The bottom line: - Alirocumab is on track for steady double-digit growth through 2030 as cardiovascular disease, precision medicine and broader biologic use keep expanding demand.